Andrew Cooper

TLDR

Andrew Cooper is CEO of CluePoints, a Belgian AI-driven clinical trial data quality platform founded in 2012, now serving many of the top 20 global pharma companies and acquired by EQT in June 2024.

Overview

Cooper was appointed CEO of CluePoints in December 2022, bringing more than 24 years of clinical trial industry and software experience. He previously served as General Manager for the eCOA Business Unit at Clario (formerly ERT) and held leadership roles at Oracle and Medidata. CluePoints uses advanced statistics, machine learning, and AI to assess the quality, accuracy, and integrity of clinical trial data. The platform has over 9,500 users, has de-risked more than 1,600 studies, and detected over 142,000 issues for its customers.